Scientific References

Jarell A, Gastman BR, Dillon LD, et al. Optimizing treatment approaches for patients with cutaneous melanoma by integrating clinical and pathologic features with the 31-gene expression profile test. J Am Acad Dermatol 2022. doi: https://doi.org/10.1016/j.jaad.2022.06.1202.

Hsueh EC, DeBloom JR, Lee JH, et al. Long-term outcomes in a multicenter, prospective cohort evaluating the prognostic 31-gene expression profile for cutaneous melanoma. JCO Precis Oncol 2021;5:589-601.

Marks E, Caruso HG, Kurley SJ, et al. Establishing an evidence-based decision point for clinical use of the 31-gene expression profile test in cutaneous melanoma. SKIN J Cutaneous Med 2019;3:239-49.

Podlipnik S, Carrera C, Boada A, et al. Early outcome of a 31-gene expression profile test in 86 AJCC stage Ib-II melanoma patients. A prospective multicenter cohort study. J Eur Acad Dermatol Venereol 2019;33:857-62.

Keller J, Schwartz TL, Lizalek JM, et al. Prospective validation of the prognostic 31-gene expression profiling test in primary cutaneous melanoma. Cancer Med 2019;8:2205-12.

Gastman BR, Zager JS, Messina JL, et al. Performance of a 31-gene expression profile test in cutaneous melanomas of the head and neck. Head Neck 2019;41:871-9.

Gastman BR, Gerami P, Kurley SJ, et al. Identification of patients at risk for metastasis using a prognostic 31-gene expression profile in subpopulations of melanoma patients with favorable outcomes by standard criteria. J Am Acad Dermatol 2019. 80:149-157. doi:10.1016/j.jaad.2018.07.028.

Zager JS, Gastman BR, Leachman S, et al. Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients. BMC Cancer 2018;18:130.

Leachman S, Covington KR, Cook RW, et al. Implications of a 31-gene expression profile test for cutaneous melanoma on AJCC-based risk assessment and adjuvant therapy trial design. Poster presented at 2018 Society for Melanoma Research International Congress.

Greenhaw BD, Zitelli JA, Brodland DG. Estimation of prognosis in invasive cutaneous melanoma: An independent study of the accuracy of a gene expression profile test. Dermatol Surg 2018;44:1494-1500. doi: 10.1097/DSS.0000000000001588.

Hsueh EC, DeBloom JR, Lee J, et al. Interim analysis of survival in a prospective, multi-center registry cohort of cutaneous melanoma tested with a prognostic 31-gene expression profile test. J Hematol Oncol 2017;10(152):1-8.

Gerami P, Cook RW, Russell MC, et al. Gene expression profiling for molecular staging of cutaneous melanoma in patients with sentinel lymph node biopsy. J Am Acad Dermatol 2015;72:780-5.e3.

Gerami P, Cook RW, Wilkinson J, et al. Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma. Clin Cancer Res 2015;21:175-83.

Yamamoto M, Sickle-Santanello B, Beard T, et al. The 31-gene expression profile test informs sentinel lymph node biopsy decisions in patients with cutaneous melanoma: results of a prospective, multicenter study. Curr Med Res Opin. 2023;1-7. doi:10.1080/03007995.2023.2165813


Dillon LD, McPhee M, Davidson RS, et al. Expanded evidence that the 31-gene expression profile test provides clinical utility for melanoma management in a multicenter study.Current Medical Research and Opinion 2022. https://doi.org/10.1080/03007995.2022.2033560


Hyams DM, Covington KR, Johnson CE, et al. Integrating the melanoma 31-gene expression profile test to surgical oncology practice within national guideline and staging recommendations. Future Oncol 2020 doi.org/10.2217/fon-2020-0827.


Scott AM, Dale PS, Conforti A, et al. Integration of a 31-gene expression profile into clinical decision-making in the treatment of cutaneous melanoma. Am Surgeon 2020. https://doi.org/10.1177/0003134820939944.


Mirsky R, Prado G, Svoboda R, et al. Management decisions made by physician assistants and nurse practitioners in cutaneous malignant melanoma patients: Impact of a 31-gene expression profile test. J Drugs Dermatol 2018;17:1220-3.


Schuitevoerder D, Heath M, Cook RW, et al. Impact of gene expression profiling on decision-making in clinically node negative melanoma patients after surgical staging. J Drugs Dermatol 2018;17:196-9.


Svoboda RM, Glazer AM, Farberg AS, et al. Factors affecting dermatologists' use of a 31-gene expression profiling test as an adjunct for predicting metastatic risk in cutaneous melanoma. J Drugs Dermatol 2018;17:544-7.


Dillon LD, Gadzia JE, Davidson RS, et al. Prospective, multicenter clinical impact evaluation of a 31-gene expression profile test for management of melanoma patients. SKIN J Cutan Med 2018;2:111-21.


Farberg AS, Glazer AM, White R, et al. Impact of a 31-gene expression profiling test for cutaneous melanoma on dermatologists' clinical management decisions. J Drugs Dermatol 2017;16:611-6.


Ferris LK, Farberg AS, Middlebrook B, et al. Identification of high-risk cutaneous melanoma tumors is improved when combining the online American Joint Committee on Cancer Individualized Melanoma Patient Outcome Prediction Tool with a 31-gene expression profile-based classification. J Am Acad Dermatol 2017;76;818-25.e3. doi: 10.1016/j.jaad.2016.11.051.


Berger AC, Davidson RS, Poitras JK, et al. Clinical impact of a 31-gene expression profile test for cutaneous melanoma in 156 prospectively and consecutively tested patients. Curr Med Res Opin 2016;32:1599-1604. doi:10.1080/03007995.2016.1192997.

Zakria D, Brownstone N, Berman B, et al. Incorporating Prognostic Gene Expression Profile Assays into the Management of Cutaneous Melanoma: An Expert Consensus Panel Report. JCMS 2023; 7(1):556–569. doi:https://doi.org/10.25251/skin.7.1.1


Farberg AS, Marson JW, Glazer A, et al. Expert Consensus on the Use of Prognostic Gene Expression Profiling Tests for the Management of Cutaneous Melanoma: Consensus from the Skin Cancer Prevention Working Group. Dermatol. Ther 2022; 12:807–823. doi:https://doi.org/10.1007/s13555-022-00709-x


Wisco OJ, Marson JW, Litchman GH, et al.Improved cutaneous melanoma survival stratification through integration of 31-gene expression profile testing with the American Joint Committee on Cancer 8th Edition Staging.  Melanoma Research 2022. doi: 10.1097/CMR.0000000000000804


Kwatra SG, Hines H, Semenov YR, et al. A dermatologist's guide to implementation of gene expression profiling in the management of melanoma.  J Clin Aesthet Dermatol 2020;13(Suppl 1):s3-s14.


Litchman GH, Prado G, Teplitz RW & Rigel DS.  A systematic review and meta-analysis of gene expression profiling for primary cutaneous melanoma prognosis.  SKIN J Cutaneous Med 2020;4:221-37.


Greenhaw BN, Covington KR, Kurley SJ, et al. Molecular risk prediction in cutaneous melanoma: a meta-analysis of the 31-gene expression profile prognostic test in 1,479 patients. J Am Acad Dermatol 2020. doi.org/10.1016/j.jaad.2020.03.053


Berman B, Ceilley R, Cockerell C, et al. Appropriate use criteria for the integration of diagnostic and prognostic gene expression profile assays into the management of cutaneous malignant melanoma: an expert panel consensus-based modified Delphi process assessment. SKIN J Cutaneous Med 2019;3:291-306.


Dubin DP, Dinehart SM & Farberg AS. Level of evidence review for a gene expression profile test for cutaneous melanoma. Am J Clin Dermatol 2019;20:763-70.


Winkelmann RR, Farberg AS, Glazer AM, et al. Integrating skin cancer-related technologies into clinical practice. Dermatol Clin 2017;35:565-76.


Ahmed K, Siegel JJ, Morgan-Linnell SK, LiPira K, et al. Attitudes of patients with cutaneous melanoma toward prognostic testing using the 31-gene expression profile test.Cancer Medicine 2022;00:1- 8.

Cook RW, Monzon FA, Caruso HG, et al. Identification of melanoma patients with low risk of sentinel lymph node positivity and favorable prognosis using a 31-gene expression profile (GEP) test. Poster at Society for Melanoma Research (SMR) Congress: Nov 20-23, 2019; Salt Lake City, Utah.

Monzon FA, Caruso HG, Covington KR, et al. Identification of T1-T2 melanoma patients at low risk for a positive sentinel lymph node using the 31-gene expression profile test. Oral presentation at 8th International Congress on Cancer Metastasis (ICCM): October 25-27, 2019; San Francisco, California.

Thorpe R, Covington K, Caruso H, et al. Development and validation of a clinically useful nomogram incorporating molecular clinicopathologic factors to predict risk of recurrence in patients with cutaneous melanoma. Oral presentation at American Society for Dermatologic Surgery (ASDS) Annual Meeting, October 24-27, 2019; Chicago, Illinois.

Estrada S, Covington KR, Caruso HG, et al. Identification of T1 melanoma patients at low risk for a positive sentinel lymph node (SLN) using a 31-gene expression profile (31-GEP). Poster at American Society of Dermatopathology (ASDP) 56th Annual Meeting: October 17-20, 2019; San Diego, California.

Prado G, Teplitz RW, Covington KR, et al. The prognostic 31-gene expression profile (31-GEP) test improves risk prediction in cutaneous melanoma (CM) patients within current AJCC stages. Poster at 2019 Fall Clinical Dermatology Conference for PAs and NPs: May 31-June 2, 2019; Scottsdale, Arizona.

Bamboat ZM, Konstantinidis IT, Kuk D, et al. Observation after a positive sentinel lymph node biopsy in patients with melanoma. Ann Surg Oncol 2014;21:3117–23.


Ellis MC, Weerasinghe R, Corless CL, et al. Sentinel lymph node staging of cutaneous melanoma:  predictors and outcomes. Am J Surg  2010;199:663-8.


Farberg AS, Glazer AM, Winkelmann RR, et al. Assessing genetic expression profiles in melanoma prognosis. Dermatol Clin 2017;35:545-50.


Joyce KM, McInerney NM, Piggott RP, et al. Analysis of sentinel node positivity in primary cutaneous melanoma: an 8-year single institution experience. Ir J Med Sci 2017;186:847-53.


Kaufman H, Amatruda T, Nemunaitis, JJ et al. Tumor size and clinical outcomes in melanoma patients (MEL pts) treated with talimogene laherparepvec (T-VEC). J Clin Oncol 2015;33:9074.


Livingstone E, Krajewski C, Eigentler TK, et al. Prospective evaluation of follow-up in melanoma patients in Germany - results of a multicenter and longitudinal study. Eur J Cancer 2015;51:653-67.


Menzies AM, Haydu LE, Carlino MS, et al. Inter- and intra-patient heterogeneity of response and progression to targeted therapy in metastatic melanoma. PLoS One 2014;9:e85004.


Moody, JA, Ali RF, Carbone AC, et al. Complications of sentinel lymph node biopsy for melanoma - A systematic review of the literature. Eur J Surg Oncol 2017;43:270-7.


Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med 2014;370:599-609.


Nishino M, Giobbie-Hurder A, Ramaiya NH, et al. Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome. J Immunother Cancer 2014;2:40.


Park TS, Phan GQ, et al. Routine computer tomography imaging for the detection of recurrences in high-risk melanoma patients. Ann Surg Oncol 2017;24:947-51.


Podlipnik S, Carrera C, Sanchez M, et al. Performance of diagnostic tests in an intensive follow-up protocol for patients with American Joint Committee on Cancer (AJCC) stage IIB, IIC, and III localized primary melanoma: A prospective cohort study. J Am Acad Dermatol 2016;75:516-24.


Poklepovic AS, Carvajal RD. Prognostic value of low tumor burden in patients with melanoma. Oncology 2018;32:e90-e96.


Ribas A, Hamid O, Daud A, et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. J Am Med Assoc 2016;315:1600-9.


Shaikh WR, Dusza SW, Weinstock MA, et al. Melanoma thickness and survival trends in the United States, 1989 to 2009. J Natl Cancer Inst 2016;108. doi:10.1093/jnci/djv294.


Whiteman DC, Baade PD, Olsen CM. More people die from thin melanomas (1 mm) than from thick melanomas (>4 mm) in Queensland, Australia. J Invest Dermatol 2015;135:1190-3.


Winkelmann RR, Farberg AS, Glazer AM, et al. Noninvasive technologies for the diagnosis of cutaneous melanomaDermatol Clin 2017;35:453-6.

Carvajal RD, Antonescu CR, Wolchok JD, et al. KIT as a therapeutic target in metastatic melanoma. JAMA 2011;305:2327-34.


Cheng L, Lopez-Beltran A, Massar F, et al. Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine. Mod Pathol 2017;2:29.


Curtin JA, Busam K, Pinkel D, et al. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006;24:4340-46.


Davies H, Bignell GR, Stephens P, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.


Dumaz N, André J, Sadoux A, et al. Driver KIT mutations in melanoma cluster in four hotspots. Melanoma Res 2015;25:88-90.


Dummer R, Schadendorf D, Ascierto PA, et al. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2017;18:435-45.


Fedorenko IV, Gibney GT & Smalley KSM. NRAS mutant melanoma: biological behavior and future strategies for therapeutic management. Oncogene 2013;32:3009-18.


Gong HZ, Zheng HY & Li J. The clinical significance of KIT mutations in melanoma: a meta-analysis. Melanoma Res 2018;28:259-70.


Guo J, Si L, Kong Y, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 2011; 29:2904-9.


Hayward NK, Wilmott JS, Waddell N, et al. Whole-genome landscapes of major melanoma subtypes. Nature 2017;545:175-80.


Hodi FS, Corless CL, Giobbie-Hurder A, et al. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol 2013;31:3182-90.


Hodi FS, Friedlander P, Corless C, et al. Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol 2008;26:2046-51.


Holderfield M, Deuker, MM, McCormick F, et al. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer 2014;14:455-67.


Johnson DB, Lovly CM, Flavin M, et al. Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies. Cancer Immunol Res 2015;3: 288-95.


Koelblinger P & Dummer R. Targeted treatment of advanced NRAS-mutated melanoma. Oncotarget 2017;8:84616-17.


Li MM, Datto M, Duncavage EJ, et al. Standards and guidelines for the interpretation and reporting of sequence variants in cancer. J Mol Diagn 2017;19:4-23.


Long GV, Fung C, Menzies AM, et al. Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma. Nature Commun 2014;5:5694.


Long G, Hauschild A, Santinami M, et al. Adjuvant dabrafenib plus trametinib in Stage III BRAF-mutated melanoma. New Engl J Med 2017;77:1813-23.


Lutzky J, Bauer J & Bastian BC. Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment Cell Melanoma Res 2008;21:492-3.


Posch C, Vujic I, Monshi B, et al. Searching for the chokehold of NRAS mutant melanoma. J Invest Dermatol 2016;136:1330-6.


Reddy BY, Miller DM & Tsao H. Somatic driver mutations in melanoma. Cancer 2017;123:2104-17.


Richtig G, Hoeller C, Kashofer K, et al. Beyond the BRAFV600E hotspot: biology and clinical implications of rare BRAF gene mutations in melanoma patients. Br J Dermatol 2017;177:936-44.


Rizos H, Menzies AM, Pupo GM, et al. BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clin Cancer Res 2014;20:1965-77.


Schadendorf D, Fisher DE, Garbe C, et al. Melanoma. Nat Rev Dis Primers 2015;1:15003.


Schubbert S, Shannon K & Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007;7:295-308.


The Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell 2015;161:1681-96.


Order DecisionDx®-Melanoma

For Information

Call: 866-788-9007

NOW AVAILABLE: New Integrated Test Result for Precise and Personalized Risk of Recurrence

On-Demand Educational Programs

What's Next?


Order a test

Scroll to Top
Scroll to Top